Patents by Inventor Boqin QIANG

Boqin QIANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Application of clofoctol for manufacturing pharmaceutical product for treating human neuroglioma
    Patent number: 10987318
    Abstract: The present invention discloses an application of clofoctol for manufacturing a pharmaceutical product for treating human neuroglioma. The clofoctol is a pharmaceutical product for treating an upper respiratory tract infection. The clofoctol exerts a significant and specific inhibition of a glioma stem cell activity relative to a human neuroglioma cell or a normal human astroglia, human embryonic kidney cell, and human neural stem cell. A glioma stem cell treated with the clofoctol exhibited significantly reduced self-renewal, tumorsphere formation, and in vivo tumor formation in a nude rat. In vivo experiments using a zebrafish glioma transplantation model and a nude rat glioma transplantation model provided in vivo verification for the therapeutic efficacy of the pharmaceutical product against glioma.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: April 27, 2021
    Assignee: Institute of Medical Sciences, Chinese Academy of Medical Sciences
    Inventors: Xiaozhong Peng, Yan Hu, Wei Han, Boqin Qiang
  • APPLICATION OF CLOFOCTOL FOR MANUFACTURING PHARMACEUTICAL PRODUCT FOR TREATING HUMAN NEUROGLIOMA
    Publication number: 20200060988
    Abstract: The present invention discloses an application of clofoctol for manufacturing a pharmaceutical product for treating human neuroglioma. The clofoctol is a pharmaceutical product for treating an upper respiratory tract infection. The clofoctol exerts a significant and specific inhibition of a glioma stem cell activity relative to a human neuroglioma cell or a normal human astroglia, human embryonic kidney cell, and human neural stem cell. A glioma stem cell treated with the clofoctol exhibited significantly reduced self-renewal, tumorsphere formation, and in vivo tumor formation in a nude rat. In vivo experiments using a zebrafish glioma transplantation model and a nude rat glioma transplantation model provided in vivo verification for the therapeutic efficacy of the pharmaceutical product against glioma.
    Type: Application
    Filed: March 20, 2017
    Publication date: February 27, 2020
    Applicant: Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences
    Inventors: Xiaozhong PENG, Yan HU, Wei HAN, Boqin QIANG